Disclosures for "Harvard Biomarkers Study 2.0: A Longitudinal Multi-modal Platform for Biomarker Discovery in Parkinson’s Disease and Related Disorders"
-
Dr. El Kodsi has nothing to disclose.
-
Author has nothing to disclose
-
Ms. Laun has nothing to disclose.
-
Miss Gilbert has nothing to disclose.
-
Dr. Rai has nothing to disclose.
-
Miss Gemos has nothing to disclose.
-
Ms. Con has nothing to disclose.
-
Mr. Vaidya has nothing to disclose.
-
Mr. Nasir has nothing to disclose.
-
Dr. Nazeen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dacapo Brainscience, Inc..
-
Dr. Kuzkina has nothing to disclose.
-
Dr. Barrasa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Robigo.
-
Dr. Khurana has received personal compensation for serving as an employee of DaCapo BrainScience. An immediate family member of Dr. Khurana has received personal compensation for serving as an employee of Arbor Therapeutics. Dr. Khurana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Khurana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Yoda Pharmaceuticals. Dr. Khurana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Khurana has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DaCapo Brainscience. Dr. Khurana has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Mission MSA. Dr. Khurana has stock in DaCapo Brainscience. The institution of Dr. Khurana has received research support from Sanofi. The institution of Dr. Khurana has received research support from Janssen. The institution of Dr. Khurana has received research support from Biohaven. The institution of Dr. Khurana has received research support from Tiziana Life Sciences. Dr. Khurana has received intellectual property interests from a discovery or technology relating to health care.